Study finds hundreds of COVID-19 machine learning models are riddled with flaws, making them unreliable.
Imaging-based machine learning models publicized as tools for diagnosing COVID-19 cannot produce the desired results and are not suitable for use, according to industry experts.
To date, more than 300 COVID-19 machine learning models, built with chest X-rays and chest CTs, have been developed and discussed in scientific literature since the beginning of the pandemic. But, due to methodological short-comings, biases, and bad data, they’re of no real use clinically, said researchers from the University of Cambridge. The team published their findings March 15 in Nature Machine Intelligence.
“Our review finds that none of the models identified are of potential clinical use due to methodological flaws and/or underlying biases,” said the team led by first author Michael Roberts, Ph.D., from the Cambridge department of applied mathematics and theoretical physics. “This is a major weakness, given the urgency with which validated COVID-19 models are needed.”
From the beginning of the pandemic, there was an overwhelming desire for tools that could help providers detect and diagnose the virus as quickly as possible. But, because machine learning algorithms require high-quality data, the rapidly evolving landscape and different presentations of the disease and how it behaves made it a challenge to create reliable models.
“The international machine learning community went to enormous efforts to tackle the COVID-19 pandemic using machine learning,” said joint senior author James Rudd, MB, BCh, Ph.D., from the Cambridge department of medicine. “These early studies show promise, but they suffer from a high prevalence of deficiencies in methodology and reporting, with none of the literature we reviewed reaching the threshold of robustness and reproducibility essential to support use in clinical practice.”
For their study, the team identified 2,212 studies and whittled them down to 62 for a systematic review. Their analysis showed that no study was acceptable with each one having critical flaws, such as poor quality data, poor applications of machine learning methodology, poor reproducibility, or study design bias. For example, many training data sets that used images of adults for their COVID-19 data actually relied on pediatric images for non-COVID-19 information.
“However, since children are far less likely to get COVID-19 than adults,” Roberts explained, “all the machine learning model could usefully do was to tell the difference between children and adults, since including images from children made the model highly biased.”
In many cases, studies did not specify the origin of their data or the same data was used to both test and train models. Other studies used publicly available “Frankenstein datasets” that had evolved and merged over time and were no longer able to provide reproducible results.
In addition, the team noted, many machine models were trained on datasets from single institutions – far too little information, and far less varied, to reliably be useful in a different facility or geographic location.
“The data needs to be diverse and ideally international, or else you’re setting your machine learning model up to fail when it’s tested more widely,” Rudd said.
But, it is possible to salvage machine learning for COVID-19 and make it useful and effective as the pandemic lingers, the team said. To develop more effective models, they offered these suggestions:
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Study Assesses Lung CT-Based AI Models for Predicting Interstitial Lung Abnormality
September 6th 2024A machine-learning-based model demonstrated an 87 percent area under the curve and a 90 percent specificity rate for predicting interstitial lung abnormality on CT scans, according to new research.